Truls S Ingebrigtsen1, Jacob L Marott2, Jørgen Vestbo3, Jesper Hallas4, Børge G Nordestgaard5, Morten Dahl6, Peter Lange7. 1. Department of Respiratory Medicine, Odense University Hospital and Clinical Institute, University of Southern Denmark, Odense, Denmark; The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark. Electronic address: trulsingebrigtsen@gmail.com. 2. The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark. 3. Department of Respiratory Medicine, Odense University Hospital and Clinical Institute, University of Southern Denmark, Odense, Denmark; Respiratory Research Group, Manchester Academic Health Sciences Centre, University Hospital South Manchester NHS Foundation Trust, Manchester, England. 4. Department of Clinical Pharmacology, Odense University Hospital and Clinical Institute, University of Southern Denmark, Odense, Denmark. 5. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark; The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark. 6. Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 7. The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark; Respiratory Section, Hvidovre Hospital, Copenhagen University Hospital, Copenhagen, Denmark; Department of Social Medicine, Institute of Public Health, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: We wished to characterize undertreatment in COPD. METHODS: Among 5,812 individuals with COPD defined by FEV1/FVC < 0.7 participating in the Copenhagen General Population Study, we identified 920 individuals with FEV1 < 60% predicted. Prescriptions were identified in an all-inclusive nationwide registry. For each individual, we examined treatment with medication in the year before the day of the baseline examination, as well as treatment in the first year after the examination. Multivariable logistic regression analyses were applied in individuals with FEV1 < 60% predicted to identify predictors of treatment in the first year after baseline. RESULTS: Only 30% of individuals with COPD and FEV1 < 60% predicted were treated with medication in the year before the examination, whereas 42.2% were treated with medication in the first year after. Reporting six to 10 previous respiratory infections during the preceding 10 years that required consulting a doctor and/or staying home from work was the strongest predictor of treatment with medication (OR, 7.9; 95% CI, 3.5-19.8; P < .001). Breathlessness, low FEV1, previous admissions with a discharge diagnosis of COPD, and former smoking were also predictors of treatment with medication, whereas comorbidity predicted lack of treatment. In subgroup analysis, among individuals with FEV1 < 50% predicted, visits to the general practitioner and age were additional predictors of treatment, whereas male sex and being a widow/widower predicted lack of treatment. CONCLUSIONS: In this study, we observed important characteristics of a major undertreatment in individuals with COPD in the general population. Previous reported respiratory infections were the strongest predictors of treatment with medications, which indicates that most COPD treatment is initiated because of acute exacerbations.
BACKGROUND: We wished to characterize undertreatment in COPD. METHODS: Among 5,812 individuals with COPD defined by FEV1/FVC &lt; 0.7 participating in the Copenhagen General Population Study, we identified 920 individuals with FEV1 &lt; 60% predicted. Prescriptions were identified in an all-inclusive nationwide registry. For each individual, we examined treatment with medication in the year before the day of the baseline examination, as well as treatment in the first year after the examination. Multivariable logistic regression analyses were applied in individuals with FEV1 &lt; 60% predicted to identify predictors of treatment in the first year after baseline. RESULTS: Only 30% of individuals with COPD and FEV1 &lt; 60% predicted were treated with medication in the year before the examination, whereas 42.2% were treated with medication in the first year after. Reporting six to 10 previous respiratory infections during the preceding 10 years that required consulting a doctor and/or staying home from work was the strongest predictor of treatment with medication (OR, 7.9; 95% CI, 3.5-19.8; P &lt; .001). Breathlessness, low FEV1, previous admissions with a discharge diagnosis of COPD, and former smoking were also predictors of treatment with medication, whereas comorbidity predicted lack of treatment. In subgroup analysis, among individuals with FEV1 &lt; 50% predicted, visits to the general practitioner and age were additional predictors of treatment, whereas male sex and being a widow/widower predicted lack of treatment. CONCLUSIONS: In this study, we observed important characteristics of a major undertreatment in individuals with COPD in the general population. Previous reported respiratory infections were the strongest predictors of treatment with medications, which indicates that most COPD treatment is initiated because of acute exacerbations.
Authors: Truls S Ingebrigtsen; Jacob L Marott; Børge G Nordestgaard; Peter Lange; Jesper Hallas; Morten Dahl; Jørgen Vestbo Journal: J Gen Intern Med Date: 2014-09-23 Impact factor: 5.128
Authors: Michael Poon; Priscila Pequeno; Shawn D Aaron; Matthew B Stanbrook; Harvey H Wong; Peter Cram; Andrea S Gershon Journal: ERJ Open Res Date: 2022-04-25
Authors: Earl S Ford; David M Mannino; Anne G Wheaton; Letitia Presley-Cantrell; Yong Liu; Wayne H Giles; Janet B Croft Journal: PLoS One Date: 2014-04-21 Impact factor: 3.240
Authors: Anders Boeck Jensen; Pope L Moseley; Tudor I Oprea; Sabrina Gade Ellesøe; Robert Eriksson; Henriette Schmock; Peter Bjødstrup Jensen; Lars Juhl Jensen; Søren Brunak Journal: Nat Commun Date: 2014-06-24 Impact factor: 14.919
Authors: James F Donohue; Nicola A Hanania; Barry Make; Matthew C Miles; Donald A Mahler; Lisa Curry; Robert Tosiello; Alistair Wheeler; Donald P Tashkin Journal: Chest Date: 2014-12 Impact factor: 9.410
Authors: Andrea S Gershon; Priscila Pequeno; Amanda Alberga Machado; Shawn D Aaron; Tetyana Kendzerska; Jin Luo; Matthew B Stanbrook; Wan C Tan; Joan Porter; Teresa To Journal: Chest Date: 2021-06-16 Impact factor: 9.410
Authors: Margaret K Pasquale; Yihua Xu; Christine L Baker; Kelly H Zou; John G Teeter; Andrew M Renda; Cralen C Davis; Theodore C Lee; Joel Bobula Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-01-14